Loading
Jabez Biosciences makes JBZ-001, a tablet that blocks an enzyme cancer cells need to build new DNA and RNA building blocks. It is in a first trial in people with advanced solid tumours and non-Hodgkin lymphoma.
Jabez Biosciences, Inc., with releases datelined Zionsville, Indiana, describes itself as a lean drug development company that licenses academic discoveries into cancer therapies it calls '3-S' (seamless, scalable, synergistic). Its lead compound JBZ-001 is an oral inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme of pyrimidine synthesis. A first-in-human phase 1 dose-escalation and expansion trial (NCT06801002) in refractory solid tumours and non-Hodgkin lymphoma dosed its first patient at The Ohio State University Comprehensive Cancer Center in April 2025, added a second site in August 2025, and first-in-human pharmacokinetic and pharmacodynamic data were presented at AACR 2026. The company is raising money from the public through a Regulation A+ offering. Its first registered cancer trial, NCT06801002, was posted on ClinicalTrials.gov in January 2025.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/